Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

Open source

DOI: 10.1016/s1470-2045(24)00338-3
Published: 2024 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00338-3,
  title = {Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.},
  author = {Bührer E and Kicinski M and Mandala M and Pe M and Long GV and Atkinson V and Blank CU and Haydon A and Dalle S and Khattak A and Carlino MS and Meshcheryakov A and Sandhu S and Puig S and Schadendorf D and Jamal R and Rutkowski P and van den Eertwegh AJM and Coens C and Grebennik D and Krepler C and Robert C and Eggermont AMM},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00338-3},
  url = {https://doi.org/10.1016/s1470-2045(24)00338-3}
}

RIS

TY  - JOUR
TI  - Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
AU  - Bührer E
AU  - Kicinski M
AU  - Mandala M
AU  - Pe M
AU  - Long GV
AU  - Atkinson V
AU  - Blank CU
AU  - Haydon A
AU  - Dalle S
AU  - Khattak A
AU  - Carlino MS
AU  - Meshcheryakov A
AU  - Sandhu S
AU  - Puig S
AU  - Schadendorf D
AU  - Jamal R
AU  - Rutkowski P
AU  - van den Eertwegh AJM
AU  - Coens C
AU  - Grebennik D
AU  - Krepler C
AU  - Robert C
AU  - Eggermont AMM
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00338-3
UR  - https://doi.org/10.1016/s1470-2045(24)00338-3
ER  -

APA

E, B., M, K., M, M., M, P., GV, L., V, A., CU, B., A, H., S, D., A, K., MS, C., A, M., S, S., S, P., D, S., R, J., P, R., AJM, V. D. E., C, C., D, G., C, K., C, R., & AMM, E. (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00338-3

Source records

pubmed · retrieved 2026-09-26T22:59:25.166Z
europe-pmc · retrieved 2026-09-26T22:59:25.171Z
hal · retrieved 2026-09-26T22:59:25.250Z